Novo Nordisk
Novo Nordisk Expands Production Capabilities with $11bn Catalent Deal
Novo Nordisk's parent company acquires three manufacturing sites to enhance drug supply, focusing on obesity and diabetes medications.
See moreNovo Nordisk's parent company acquires three manufacturing sites to enhance drug supply, focusing on obesity and diabetes medications.
See moreNovo Nordisk tjekker ind med en kæmpe købsaftale, der vil styrke produktionen af deres populære vægttabsmedicin Arbeider! Læs videre for at finde ud af, hvad denne handel betyder for fremtiden!
See more